Professor and Associate Dean University of North Carolina School of Pharmacy Chapel Hill, North Carolina
The speaker will articulate the position that the breadth of data still supports the primary use of 4 factor PCCs for acute ICH management. Until head-to-head trials become available, we should continue to use them first line.
